

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



利君國際醫藥(控股)有限公司

Lijun International Pharmaceutical (Holding) Co., Ltd.

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2005)

ANNOUNCEMENT PURSUANT TO RULE 13.09(2)(a) OF THE LISTING RULES

TERMINATION OF THE SALES AND PURCHASE AGREEMENTS

The Company was informed by each of Prime United Industries and China Pharmaceutical that on 31 October 2013, being the Long Stop Date of each Agreement, the above mentioned conditions precedent of the Agreements had not yet been fulfilled and the Vendors decided not to extend the Long Stop Date.

The Board is of the view that the termination of the Agreements would not have any material adverse effect on the operation and financial position of the Group and would not have any material impact on the long term development of the Group.

This announcement is made by Lijun International Pharmaceutical (Holding) Co., Ltd. (the “**Company**” and its subsidiaries, collectively the “**Group**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on the Stock Exchange of Hong Kong Limited (“**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Future Ordinance (Chapter 571, Laws of Hong Kong) (the “**SFO**”).

References are made to the announcements of the Company dated 28 December 2012, 3 January 2013, 6 May 2013, 28 June 2013, 2 August 2013 and 30 August 2013 (the “**Announcements**”) which, among other things, disclosed that each of Prime United Industries and China Pharmaceutical, as Vendors and being substantial shareholders of the Company, had entered into an Agreement with Sichuan Kelun Pharmaceutical Co., Ltd., as Purchaser, respectively, pursuant to which each of Prime United Industries and China Pharmaceuticals has agreed to sell to the Purchaser 180,000,000 shares and 180,000,000 shares of the Company at HK\$2.9167 per share (representing approximately 6.14% and 6.14% of the issued share capital of the Company respectively as at the date of this announcement). Capitalised terms used in this announcement shall have the same meanings as those defined in the Announcements unless otherwise stated.

Pursuant to the terms of each Agreement (as amended by the Vendors and Purchaser from time to time as disclosed in the Announcements), if all conditions precedent set out in the Agreement cannot be fulfilled in full or waived or exempted before 31 October 2013 (the “**Long Stop Date**”) or such other date as agreed between the Purchaser and each respective Vendor in writing, the Agreement shall be terminated immediately and the parties to the Agreement shall not be under any obligation to continue the performance of the responsibilities and obligations under the Agreement.

The Company was informed by each of Prime United Industries and China Pharmaceutical that on 31 October 2013, being the Long Stop Date of each Agreement, the above mentioned conditions precedent of the Agreements had not been entirely fulfilled and the parties fail to agree on further extension of the Long Stop Date.

On 31 October 2013, China Pharmaceutical entered into a termination agreement with the Purchaser to record the termination of the Agreement between China Pharmaceutical and the Purchaser. No termination agreement was entered into between Prime United Industries and the Purchaser.

The Board is of the view that the termination of the Agreements would not have any material adverse effect on the operation and financial position of the Group and would not have any material impact on the long term development of the Group.

Shareholders of the Company and potential investors are advised to exercise caution in dealing in the shares of the Company.

By Order of the Board
Chan Ka Kit
Company Secretary

Hong Kong, 1 November 2013

As at the date of this announcement, the Board comprises Mr. Wu Qin, Mr. Qu Jiguang, Mr. Xie Yunfeng, Mr. Wang Xianjun and Mr. Duan Wei as executive Directors, and Mr. Wang Yibing, Mr. Leung Chong Shun and Mr. Chow Kwok Wai as independent non-executive Directors.

All the Directors jointly and severally accept full responsibility for the accuracy of information contained in this announcement and confirm, having made all reasonable inquiries, that to the best of their knowledge, opinions expressed in this announcement have been arrived at after due and careful consideration and there are no other facts not contained in this announcement, the omission of which would make any statement in this announcement misleading.